Clear evidence supports a role for circulating and locally-produced osteocalcin (OC) in the pathophysiology of cardiovascular (CV) lesions and CV risk, also in combination with metabolic changes, including type 2 diabetes mellitus (T2DM). Reduced plasma OC levels are associated with greater incidence of pathological CV changes, like arterial and valvular calcification, coronary and carotid atherosclerosis and increased carotid intima-media thickness. The actual relationship between OC levels and incidence of major CV events is, however, still unclear. Moreover, reduced circulating OC levels have been mostly associated with insulin resistance, metabolic syndrome or T2DM, indicating relevant OC actions on pancreatic β-cells and insulin secretion and activity. Based on these observations, this review article will attempt to summarize the current evidence on the potential usefulness of circulating OC as a biomarker for CV and metabolic risk, also evaluating the currently open issues in this area of research.

Osteocalcin as a potential risk biomarker for cardiovascular and metabolic diseases / P. Magni, C. Macchi, C.R. Sirtori, M.M. Corsi Romanelli. - In: CLINICAL CHEMISTRY AND LABORATORY MEDICINE. - ISSN 1437-4331. - 54:10(2016 Oct), pp. 1579-1587. [10.1515/cclm-2015-0953]

Osteocalcin as a potential risk biomarker for cardiovascular and metabolic diseases

P. Magni
Primo
;
C. Macchi
Secondo
;
M.M. Corsi Romanelli
Ultimo
2016-10

Abstract

Clear evidence supports a role for circulating and locally-produced osteocalcin (OC) in the pathophysiology of cardiovascular (CV) lesions and CV risk, also in combination with metabolic changes, including type 2 diabetes mellitus (T2DM). Reduced plasma OC levels are associated with greater incidence of pathological CV changes, like arterial and valvular calcification, coronary and carotid atherosclerosis and increased carotid intima-media thickness. The actual relationship between OC levels and incidence of major CV events is, however, still unclear. Moreover, reduced circulating OC levels have been mostly associated with insulin resistance, metabolic syndrome or T2DM, indicating relevant OC actions on pancreatic β-cells and insulin secretion and activity. Based on these observations, this review article will attempt to summarize the current evidence on the potential usefulness of circulating OC as a biomarker for CV and metabolic risk, also evaluating the currently open issues in this area of research.
atherosclerosis; cardiovascular risk; metabolic syndrome; osteocalcin; type 2 diabetes mellitus
Settore MED/05 - Patologia Clinica
Settore MED/04 - Patologia Generale
Settore MED/13 - Endocrinologia
Settore MED/46 - Scienze Tecniche di Medicina di Laboratorio
10-feb-2016
Article (author)
File in questo prodotto:
File Dimensione Formato  
cclm-2015-0953.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 735.93 kB
Formato Adobe PDF
735.93 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/365206
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 16
social impact